Immune checkpoint inhibitors combined with angiogenesis inhibitors are currently the first-line treatment for liver cancer.
However, some patients still exhibit poor therapeutic outcomes.
Platelets, as a critical component of blood, play a significant role in liver cancer progression by influencing angiogenesis and the tumor immune microenvironment.
